Categories
Health

Patient Handling Equipment Market projected to Reach USD 13.5 Billion by 2026

According to the report, The global Patient Handling Equipment market in 2019 was approximately USD 8.86 Billion. The market is expected to grow above a CAGR of 11% and is anticipated to reach over USD 13.5 Billion by 2026.

Patient handling equipment allows to move, transfer, or assist an individual or part of the body comfortably in medical facilities. While handling the patients this equipment ensures the safety of the doctors or caregivers. Mechanical equipment that is used to physically handle patients on the basis of medical conditions evaluation, generally based on the safety requirements of the caregiver, the medical, and recovery. Additionally, the patient handling equipment helps to improve care quality as well as it helps in maintaining patients’ personal hygiene.

Request Sample copy of this Report Here

Patient handling equipment is used for patients needing physical support, as well as for those seeking medical treatment or sickness. Patient handling equipment is generally used in hospitals, home care facilities, elderly care facilities, and rehabilitation centers, among others. The patient handling equipment assures the safety of all physicians when treating patients. Increasing hospital admissions due to upsurge in COVID-19 cases worldwide is a major factor fueling the growth of the target market.

The patient handling equipment market is segmented into type, application, end-user, and region segment. The type segment is segmented into medical beds, wheelchairs and scooters, mechanical lifting & transfer equipment, ambulatory aid devices, bathroom safety supplies, and others. Based on the application segment the target market is divided as acute & critical care, long term care, mobility assistance, fall prevention, and others. Also, based on the end-user segment the target market is segregated into hospitals, home care settings, elderly care facilities, and others.

Browse detail report Here

Some of the essential players operating in the patient handling equipment market, but not restricted to include Arjo, Drive DeVilbiss Healthcare, Hill-Rom Holdings, Invacare Corporation, Handicare, GF Health Products, Etac, Joerns Healthcare, Medline Industries, Inc., Prism Medical UK, Malvestio, Ossenberg, EZ Way, Inc., LINET, McAuley Medical, Mangar Health, Savaria, Stryker Corporation, AirPal, Inc., Antano Group, Stiegelmeyer, PARAMOUNT BED CO., LTD., Lojer Oy, Guldmann, and SM Scientific Instruments amongst others.

Contact Us:

Facts & Factors

USA: 1 (347) 690-0211

Email: [email protected]

Web: https://www.fnfresearch.com

Categories
Health

Inhalation Therapy Nebulizer Market Expected to Reach USD 1,010 Million by 2026

According to the report, The global Inhalation Therapy Nebulizer market in 2019 was approximately USD 620 Million. The market is expected to grow above a CAGR of 7.6% and is anticipated to reach over USD 1,010 Million by 2026.

Inhalation therapies are a collection of pulmonary or lung therapists, procedures intended to either regain or enhance breathing capacity of patients with different illnesses, disorders or accidents. Inhalation therapy nebulizer is a medical device used for the delivery of the necessary medication in inhalation therapy. When a large dose of an inhalation drug is required it is easy. It is also used in a variety of treatments for medicines such as treating symptoms of asthma and for immediate relief. Compared with MDIs, the nebulizer can be easier to use, especially for small children, babies and anyone who has problems using an asthma inhaler. Nebulizer reduces the risk of the side effects associated with taking high doses of prescribed medicines. The nebulizer is provided for treatment of asthma, cystic fibrosis, bronchitis, common cold, COPD, and other respiratory or illness disorders. On the market, the different types of nebulizer include ultrasonic wave nebulizer, pneumatic nebulizer, and mesh nebulizer.

Sample of this report available Here

Nebulizer inhalation therapy is a respiratory system that turns the medicine into mist and applies it straight to the lungs. Inhalation therapy nebulisation procedure is widely used to treat respiratory disorders like asthma, cystic fibrosis, and COPD. Specific instruments are used to nebulise. The most commonly used machines which are rechargeable and powered by electricity.

The Inhalation Therapy Nebulizer market is segmented based on product , end user and region. On the basis of product segment the market is segmented into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers and application segment is fragmented into COPD, Cystic Fibrosis, Nasal Congestion, Asthma and Others.

Request a full TOC of this report Here

Some of the essential players operating in the Inhalation Therapy Nebulizer market, but not restricted to include 3M, AptarGroup, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., OMRON Corporation, DeVilbiss Healthcare LLC, PARI GmbH Spezialisten für effektive Inhalation, Air Liquide Medical Systems, A&D Company, GF HEALTH PRODUCTS, INC., Vyaire Medical Inc., and Trudell Medical International.

Contact Us:

Facts & Factors

USA: 1 (347) 690-0211

Email: [email protected]

Web: https://www.fnfresearch.com

Categories
Business Health

Antibody Drug Conjugates Market Size Predicted to Reach USD 4,670 Million By 2026

According to the report, The global Antibody Drug Conjugates market in 2019 was approximately USD 2,000 Million. The market is expected to grow above a CAGR of 12.9% and is anticipated to reach over USD 4,670 Million by 2026.

Antibody drug conjugates are usually used to treat cancer and therefore are better and safer than most other cancer therapies. The increased incidence of cancer growth combined with the development of the geriatric population is likely to have an impact on the Antibody-Drug Conjugates market. Moreover, major innovative progressions are likewise adding to drive the development. As estimated by the World Health Organization (WHO), the number of individuals aged 65 years or more is projected to reach 16 % of the total population by 2050, compared to 7% in 2000. Maturing has become a significant hazard factor for various illnesses including cancer and others. Consequently, the developing geriatric populace is projected to drive the development of the market over the figure time frame.

Request to Access Free Sample, Click HERE

The worldwide market for ADC is expected to be driven by the advancement of clinical innovation. The key drivers of the market are the increasing prevalence of cancer, the development of mature populations, and the increase in large populations. Besides, the expanding research exercises on immune response treatments, preclinical examination, more exploration on cutting edge tranquilize revelations and expanding research on oncology infections and the developing joint effort between research foundations, Biotechnology, and Biopharmaceuticals organizations is likewise going about as a fuel to the market and is relied upon to drive the market of ADC inside the estimate time frame. However, the significant expense of the methodology and the lack of funds can be the restriction for the development of this market.

The Antibody Drug Conjugates industry has been segmented on the basis of drugs, application, mechanism of action, and region. The drugs segment is divided into adcetris and kadcyla. Further, the mechanism of action segment is classified as HER2 antibodies and CD30 antibodies. Additionally, the application segment is classified as lymphoma, breast cancer, and others.

To Make An Inquiry About This Report, Click HERE

The major players operating in the market are Synthon Holding B.V., Seattle Genetics Inc., Sanofi S.A., Progenics Pharmaceuticals Inc., Pfizer, Inc., Immunomedics, Inc., Immunogen Inc., Genentech Inc., Celldex Therapeutics Inc., and Bayer Healthcare Pharmaceuticals among others. Major operating players in the Antibody Drug Conjugates market concentrate on manufacturing more advanced, reliable, and cost-effective masks to lead to the growth of revenues in the industry.

Contact Us:

Facts & Factors

USA: 1 (347) 690-0211

Email: [email protected]

Web: https://www.fnfresearch.com

Categories
Business Health

Erectile Dysfunction Drugs Market projected to Reach USD 2,687.6 Million By 2026

According to the report, The global Erectile Dysfunction Drugs market in 2019 is approximately USD 1,923.3 Million. The market is anticipated to grow at a CAGR of 5.0% and is projected to reach around USD 2,687.6 Million by 2026.

Erectile dysfunction or disorder (ED) is the inability to develop and maintain an erection for satisfactory sexual intercourse or activity. Erectile dysfunction or erectile disorders are the preferred terms as opposed to impotence. There are no uniform criteria defining how consistent the problem has to be and for what duration it must be present to considered ED. The emergence of several unique formulations of erectile dysfunction drugs such as topical gels, injectables, and suppositories is expected to widen the scope of treatment for erectile dysfunction.

Request to Access Free Sample, Click HERE

The global Erectile DysfunctionDrugs market is driving due to increased vascular disorders followed by the aging population across the world. Furthermore, rising psychological problems, followed by chronic diseases like diabetes, alcohol, and smoking habits are also considered as one of the major driving factors for the growth of the market. The high cost of treatment followed by government stringent regulation is considered as a major restraining factor which curbs the growth of the market. Increasing awareness in Asia Pacific countries is considered one of the major opportunities for the growth of the market during the forecast period.

In Drug type, the market is classified into sixtype’sSildenafil Citrate (Viagra), Vardenafil (Levitra/ Staxyn), Tadalafil (Cialis), Udenafil (Zydena), Lodenafil Carbonate (Helleva), Stendra/ Spedra (Avanafil), Mirodenafil (Mvix), and Others. The Sildenafil Citrate (Viagra) accounts for the largest market shares of the Erectile Dysfunction market in the year 2019. VIAGRA works for men with erectile dysfunction (ED) by increasing blood flow to the penis so it can get and keep an erection hard enough for sex. Results may vary from Person to Person. It’s been proven to help guys with all degrees of ED. VIAGRA usually starts to work within 30-60 minutes.

To Make An Inquiry About This Report, Click HERE

The report covers a detailed competitive outlook including company profiles of the key participants operating in the global Erectile DysfunctionDrugs market. The key players of Apricus Biosciences, Bayer AG, Cristália, Eli Lilly and Company, Inc., Pfizer, Inc., Dong-A-Pharmaceutical Co., Ltd., S.K. Chemicals Co., Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc. and Others

Contact Us:

Facts & Factors

USA: 1 (347) 690-0211

Email: [email protected]

Web: https://www.fnfresearch.com